Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Mohammad akheelOmfs pg
Normal cells…•Differentiate, grow, mature, divide–Regulated, balanced; cell birth=cell death•Regulation: intracell signali...
BUT if intense, prolongeddemand …• May  cell structural, functional abnormalities– Metaplasia: replacement of one cell ty...
– Dysplasia: replacement cells disordered in size,shape• Incr’d mitosis rate• Somewhat reversible, often precancerous– Neo...
Neoplasms• = Tumors = groups of neoplastic cells• Two major types: benign, malignant• Benign – “noncancerous”– Local; cell...
• Malignant – grow more rapidly; oftencalled “cancer”– Not cohesive; seldom have capsule– Irregular shape; disrupted archi...
Cancer (Neoplastic) Cells• May be:– Well-differentiated = retain normal cellfunction• Mimic normal tissue• Often benign– P...
Oncogenesis = Process ofTumor Development• Probably multi-step process Decr’d ability to differentiate andcontrol replic...
 Initation = impt change introduced into cell◦ Probably through DNA alteration◦ >1 event probably needed for tumor prod’n...
 Most tumors arise “spontaneously” w/out knowncarcinogen exposure, AND Proto-oncogenes can be inherited (ex: “breast can...
Synth DNA precursors,proteins, etc.Premitotic synth ofstructures, mol’s
Brody 42.1 – G0
 Quiescent phase outside cell cycle Most adult cells Cyclin D in low concent Rb prot hypophosph’d◦ Inhib’s expression ...
 In healthy cells, survival factors signal act’nanti-apoptotic mech’s◦ Cytokines, hormones, cell contact factors Program...
 Second pathway act’d by intracell signals, e.g.DNA damage◦ Players are p53 gene & prot; mitochondrialcytochrome c; Apaf-...
 Code for prot’s that regulate cell div/prolif’n whenturned on/off◦ Malfunctions, mutations may  oncogenesis◦ Changes w/...
50.2 Rang
 Result of act’n proto-oncogenes or inact’n tumorsuppressor genes◦ Change in growth factors, receptors Incr’d growth fac...
◦ Change in apoptotic mech’s◦ Change in telomerase expression◦ Change in local blood vessels  angiogenesis Note: Genes c...
 Affect cell division◦ Active on rapidly dividing cells Most effective during S phase of cell cycle◦ Many cause DNA dama...
 Side effects greatest in other rapidly-dividingcells◦ Bone marrow toxicity◦ Impaired wound healing◦ Hair follicle damage...
 Solid tumors◦ Growth rate decr’s as neoplasm size incr’s Outgrows ability to maintain blood supply AND Not all cells p...
 Suspended cancer cells (leukemias)◦ Killing 99.99% of 1011cancer cell burden, 107neoplasticcells remain◦ Can’t rely on h...
 Cytotoxic Agents◦ Alkylating Agents◦ Antimetabolites◦ Cytotoxic antibiotics◦ Plant derivatives Hormones◦ Suppress nat’l...
Rand 50.3
 Contain chem grps that covalently bind cellnucleophiles Impt properties of drugs◦ Can form carbonium ions C w/ 6 elect...
 Impt targets◦ G N7 – strongly nucleophilic A N1, A N3, C N3 also targets DNA becomes cross-linked w/ agent◦ Intra- or ...
Rang 50.4
42-5 structuresNitrogen Mustards•Loss Cl  intramolec cyclization of side chain Reactive ethylene immonium derivative
 Most common Prodrug – liver metab by CYP P450 MFO’s Effects lymphocytes◦ Also immunosuppressant Oral or IV usually S...
42.6 cyclophosph
42.7 nitrosoureaNitrosoureas•Also activated in vivo•Alkylate DNA BUT alk’n prot’s  toxicity
Temozolomide•Methylates G, A  improper G-T base pairing
 Cl- dissoc’s  reactive complex that reacts w/ H2Oand interacts w/ DNA  intrastrand cross-link (G N7w/ adjacent G O6) ...
 Mimic structures of normal metabolic mol’s◦ Inhibit enz’s competitively OR◦ Inc’d into macromol’s  inappropriate struct...
 Folic acid essential for synth purines, andthymidylate Folate: pteridine ring + PABA + glutamate◦ In cells, converted t...
 Folate  FH4 cat’d bydihydrofolate reductasein 2 steps:◦ Folate  FH2◦ FH2  FH4 FH4 serves as methylgrp donor (1-C uni...
 Higher affinity for enz than does FH2◦ Add’l H or ionic bond forms  Depletion FH4 in cell  depl’n dTMP “thymine-less...
50.8 Rand
Pemetrexed
45.2 RandFYI…
 5-Fluorouracil – dUMP analog also worksthrough dTMP synthesis pathway◦ Converted  “fraudulent” nucleotide FdUMP ◦ Comp...
 Gemcitabine◦ Phosph’d  tri-PO4’s “Fraudulent nucleotide”◦ Also inhib’s ribonucleotide reductase  decr’dnucleotide syn...
 Cytosine arabinoside◦ Analog of 2’dC◦ Phosph’d in vivo  cytosine arabinoside triphosphate◦ Inhibits DNA polymerase Gem...
http://www.pfeist.net/ALL/arac/images/spongo2.gif42-11Gemcitabine
 6-Mercaptopurine, 6-Thioguanine◦ Converted to “fraudulent nucleotides”◦ Inhibit enz’s nec for purine synth Fludarabine◦...
42-10Fludarabine Pentostatin
 Substances of microbial origin that preventmammalian cell division Anthracyclines◦ Doxorubicin Intercalates in DNA In...
◦ Epirubicin, mitozantrone structurally related◦ SE’s: cardiotoxicity (due to free radical prod’n), bonemarrow suppression...
◦ Dactinomycin Intercalates in DNA minor groove between adjacent GC pairs Interferes w/ RNA polymerase movement  decr’d...
DactinomycinBleomycin
 Work at mitosis Effect tubulin, therefore microtubule activity◦  Prevention spindle form’n OR◦ Stabilize (“freeze”) po...
http://biotech.icmb.utexas.edu/botany/gifs/vdes.gifVinca Alkaloids
http://biotech.icmb.utexas.edu/botany/gifs/tax.gifTaxanes: Paclitaxel, Docetaxelhttp://home.caregroup.org/clinical/altmed/...
 Etoposide, teniposide◦ From mandrake root◦ Inhibit mitoch function, nucleoside transport,topoisomerase II Campothecins:...
http://www.chemheritage.org/EducationalServices/pharm/chemo/readings/ages/ages04.gifIronotecanhttp://www.cancerquest.org/i...
 Tumors der’d from tissues responding tohormones may be hormone-dependent◦ Growth inhib’d by hormone antagonists OR other...
 Estrogens◦ Block androgen effects (ex: fosfestrol)◦ Used to recruit cells in G0  G1, so better targets forcytotoxic dru...
 Hormone antagonists◦ Tamoxifen impt in breast cancer treatment Competes w/ endogenous estrogens for receptor Inhibits ...
http://www.wellesley.edu/Chemistry/chem227/nucleicfunction/cancer/tamoxifen.gifhttp://www.neurosci.pharm.utoledo.edu/MBC33...
Rang 50.1Antitumor Agents Working through Cell Signalling
 EGFR present on many solid tumors Tyr-kinase type receptors Ligand binding  kinase cascade transcription factor synt...
 Cetuximab◦ Monoclonal Ab directed against EGFR Erbitux – Famous anti-EGFR AbDrugs Targeting Growth Factor Receptors
 Trastuzumab◦ “Humanized” mousemonoclonal Ab◦ Binds HER2 Membr prot structurallysimilar to EGFR Has integral tyr kinase...
 Imatinib (Gleevec, Glivec)◦ Small inhibitor of kinases◦ Inhibits PDGF activity via its tyr kinase receptor◦ Inhibits Bcr...
http://www.chemistrydaily.com/chemistry/upload/thumb/9/9a/200px-Imatinib_mesylate.pnghttp://dric.sookmyung.ac.kr/NEWS/jul0...
http://www.wwu.edu/depts/healthyliving/PE511info/cancer/My%20Cancer%20Webs/Symptoms%20and%20Therapy_files/image001.jpg
Chemotherapy
Chemotherapy
Chemotherapy
Chemotherapy
Chemotherapy
Chemotherapy
Chemotherapy
Upcoming SlideShare
Loading in …5
×

Chemotherapy

2,017 views

Published on

Published in: Health & Medicine, Technology

Chemotherapy

  1. 1. Mohammad akheelOmfs pg
  2. 2. Normal cells…•Differentiate, grow, mature, divide–Regulated, balanced; cell birth=cell death•Regulation: intracell signaling–Hyperplasia: new cells prod’d w/ growthstimulus via hormones, endogenous signals–Ex: hyperplasia of endometrial tissue duringmenstrual cycle is normal and necessary
  3. 3. BUT if intense, prolongeddemand …• May  cell structural, functional abnormalities– Metaplasia: replacement of one cell type by another• Thicker cell layer better accommodates irritation– Ex: bronchial epithelium chronically irritated ciliated columnar epithelial cells replaced by sevlayers cuboidal epithelium» Note: Replacement cells normal, justdifferent» Reversible
  4. 4. – Dysplasia: replacement cells disordered in size,shape• Incr’d mitosis rate• Somewhat reversible, often precancerous– Neoplasia: abnormal growth/invasion of cells• “New growth”• Neoplasm = tumor• Irreversible• Cells replicate, grow w/out control
  5. 5. Neoplasms• = Tumors = groups of neoplastic cells• Two major types: benign, malignant• Benign – “noncancerous”– Local; cells cohesive, well-defined borders– Push adjacent tissue away– Doesn’t spread beyond original site– Often has capsule of fibrous connectivetissue
  6. 6. • Malignant – grow more rapidly; oftencalled “cancer”– Not cohesive; seldom have capsule– Irregular shape; disrupted architecture– Invade surrounding cells– Can break away to form second tumor•“Metastasis” from 1oto 2osite
  7. 7. Cancer (Neoplastic) Cells• May be:– Well-differentiated = retain normal cellfunction• Mimic normal tissue• Often benign– Poorly differentiated = disorganized• Can’t tell tissue of origin• “Anaplastic”
  8. 8. Oncogenesis = Process ofTumor Development• Probably multi-step process Decr’d ability to differentiate andcontrol replication and growth
  9. 9.  Initation = impt change introduced into cell◦ Probably through DNA alteration◦ >1 event probably needed for tumor prod’n◦ Reversible unless and until: Promotion = biochem event encouragestumor form’n Gen’ly need both initiation and promotion◦ Initiators, promoters may be toxins OR radiationOR viruses)
  10. 10.  Most tumors arise “spontaneously” w/out knowncarcinogen exposure, AND Proto-oncogenes can be inherited (ex: “breast cancergene”) BUT environmental agents are known to cause DNAmutations, AND Risk factors known (Ex:◦ Cigarette smoking  lung cancer◦ UV light exposure  skin cancer) Theory: “Genetics loads the gun; the environmentpulls the trigger”
  11. 11. Synth DNA precursors,proteins, etc.Premitotic synth ofstructures, mol’s
  12. 12. Brody 42.1 – G0
  13. 13.  Quiescent phase outside cell cycle Most adult cells Cyclin D in low concent Rb prot hypophosph’d◦ Inhib’s expression prot’s impt to cycle progression◦ Binds E2F transcr’n factors Controls genes impt to DNA repl’n Growth factor binding  act’n to G1
  14. 14.  In healthy cells, survival factors signal act’nanti-apoptotic mech’s◦ Cytokines, hormones, cell contact factors Programmed cell death Cascade of proteases initiate process◦ Initiator caspases that act on effector caspases Effector caspase act’n may be through TumorNecrosis Factor Receptor
  15. 15.  Second pathway act’d by intracell signals, e.g.DNA damage◦ Players are p53 gene & prot; mitochondrialcytochrome c; Apaf-1 (prot); caspase 9 Effector caspases initiate pathway  cleavagecell constituents  cluster membr-bound“entities” (used to be cell) that arephagocytosed Anti-apoptotic genetic lesions nec for dev’tcancer◦ Apoptosis resistance characteristic of cancer cells
  16. 16.  Code for prot’s that regulate cell div/prolif’n whenturned on/off◦ Malfunctions, mutations may  oncogenesis◦ Changes w/ viruses, chem’s: point mutations, geneamplifications, chromosome translocations Two impt routes:◦ Proto-Oncogenes – code for prot’s turning cell div ON Mutations  overexpression  cancer◦ Tumor suppressor genes – code for prot’s turning celldiv OFF Mutations  repression  cancer
  17. 17. 50.2 Rang
  18. 18.  Result of act’n proto-oncogenes or inact’n tumorsuppressor genes◦ Change in growth factors, receptors Incr’d growth factors prod’d◦ Change in growth factor pathways 2ndmessenger cascades (esp tyr-kinase receptor cascades)◦ Change in cell cycle transducers Cyclins, Cdk’s, Cdk inhibitors
  19. 19. ◦ Change in apoptotic mech’s◦ Change in telomerase expression◦ Change in local blood vessels  angiogenesis Note: Genes controlling any of theseprot’s/mech’s can be considered proto-oncogenes or tumor suppressor genes Note: Dev’t malignant cancer depends on sevtransform’ns
  20. 20.  Affect cell division◦ Active on rapidly dividing cells Most effective during S phase of cell cycle◦ Many cause DNA damage Damage DNA  init’n apoptosis
  21. 21.  Side effects greatest in other rapidly-dividingcells◦ Bone marrow toxicity◦ Impaired wound healing◦ Hair follicle damage◦ Gi epith damage◦ Growth in children◦ Gametes◦ Fetus May themselves be carcinogenic
  22. 22.  Solid tumors◦ Growth rate decr’s as neoplasm size incr’s Outgrows ability to maintain blood supply AND Not all cells proliferate continuously◦ Compartments Dividing cells (may be ~5% tumor volume) Only pop’n susceptible to most anticancer drugs Resting cells (in G0); can be stim’d  G1 Not sensitive to chemotherapy, but act’d when therapy ends Cells unable to divide but add to tumor bulk
  23. 23.  Suspended cancer cells (leukemias)◦ Killing 99.99% of 1011cancer cell burden, 107neoplasticcells remain◦ Can’t rely on host immunological defense to killremaining cancer cells Diagnosis, treatment difficult if rapidly growing◦ Ex: Burkitt’s lymphoma doubles ~24 h◦ Approx 30 doublings  tumor mass of 2 cm (109cells) May be detected, if not in deep organ◦ Approx 10 add’l doublings  20 cm mass (1012cells) –lethal◦ Therefore, “silent” for first ¾ existence
  24. 24.  Cytotoxic Agents◦ Alkylating Agents◦ Antimetabolites◦ Cytotoxic antibiotics◦ Plant derivatives Hormones◦ Suppress nat’l hormone secr’n or antagonizehormone action Misc (mostly target oncogene products)
  25. 25. Rand 50.3
  26. 26.  Contain chem grps that covalently bind cellnucleophiles Impt properties of drugs◦ Can form carbonium ions C w/ 6 electrons highly reactive React w/ -NH2, -OH, -SH◦ Bifunctional (2 reactive grps) Allow cross-linking
  27. 27.  Impt targets◦ G N7 – strongly nucleophilic A N1, A N3, C N3 also targets DNA becomes cross-linked w/ agent◦ Intra- or inter-strand◦  Decr’d transcr’n, repl’n◦  Chain scission, so strand breaks◦  Inappropriate base pairing (alkylated G w/ T) Most impt: S phase repl’n (strands unwound,more susceptible)  G2 block, apoptosis
  28. 28. Rang 50.4
  29. 29. 42-5 structuresNitrogen Mustards•Loss Cl  intramolec cyclization of side chain Reactive ethylene immonium derivative
  30. 30.  Most common Prodrug – liver metab by CYP P450 MFO’s Effects lymphocytes◦ Also immunosuppressant Oral or IV usually SE’s: n/v, bone marrow dpression,hemorrhagic cystitis◦ Latter due to acrolein toxicity; ameliorated w/ SH-donors
  31. 31. 42.6 cyclophosph
  32. 32. 42.7 nitrosoureaNitrosoureas•Also activated in vivo•Alkylate DNA BUT alk’n prot’s  toxicity
  33. 33. Temozolomide•Methylates G, A  improper G-T base pairing
  34. 34.  Cl- dissoc’s  reactive complex that reacts w/ H2Oand interacts w/ DNA  intrastrand cross-link (G N7w/ adjacent G O6)  denaturation DNA◦ Nephrotoxic◦ Severe n/v ameliorated w/ 5-HT3 antagonists (decr gastricmotility) Carboplatin – fewer above SE’s, but more myelotoxic
  35. 35.  Mimic structures of normal metabolic mol’s◦ Inhibit enz’s competitively OR◦ Inc’d into macromol’s  inappropriate structures Kill cells in S phase Three main groups◦ Folate antagonists◦ Pyr analogs◦ Pur analogs
  36. 36.  Folic acid essential for synth purines, andthymidylate Folate: pteridine ring + PABA + glutamate◦ In cells, converted to polyglutamates then tetrahydrofolate (FH4)
  37. 37.  Folate  FH4 cat’d bydihydrofolate reductasein 2 steps:◦ Folate  FH2◦ FH2  FH4 FH4 serves as methylgrp donor (1-C unit) todeoxyuridine (dUMP dTMP), alsoregenerating FH2
  38. 38.  Higher affinity for enz than does FH2◦ Add’l H or ionic bond forms  Depletion FH4 in cell  depl’n dTMP “thymine-less death”  Inhib’n DNA synth Uptake through folate transport system◦ Resistance through decr’d uptake Metabolites (polyglutamate deriv’s) retained forweeks, months
  39. 39. 50.8 Rand
  40. 40. Pemetrexed
  41. 41. 45.2 RandFYI…
  42. 42.  5-Fluorouracil – dUMP analog also worksthrough dTMP synthesis pathway◦ Converted  “fraudulent” nucleotide FdUMP ◦ Competitive inhibitor for thymidylate synthetaseactive site, but can’t be converted to dTMP◦ Covalently binds thymidylate synthetase◦ Mech action uses all 3routes  decr’d DNAsynthesis, also transcr’n/transl’n inhib’n
  43. 43.  Gemcitabine◦ Phosph’d  tri-PO4’s “Fraudulent nucleotide”◦ Also inhib’s ribonucleotide reductase  decr’dnucleotide synth Capecitabine is prodrug◦ Converted to 5FU in liver, tumor Enz impt to conversion overexpressed in cancer cells (?)
  44. 44.  Cytosine arabinoside◦ Analog of 2’dC◦ Phosph’d in vivo  cytosine arabinoside triphosphate◦ Inhibits DNA polymerase Gemcitabine – araC analog◦ Fewer SE’s
  45. 45. http://www.pfeist.net/ALL/arac/images/spongo2.gif42-11Gemcitabine
  46. 46.  6-Mercaptopurine, 6-Thioguanine◦ Converted to “fraudulent nucleotides”◦ Inhibit enz’s nec for purine synth Fludarabine◦ Converted to triphosphate◦ Mech action sim to ara-C Pentostatin◦ Inhibits adenosine deaminase Catalyzes adenosine  inosine◦ Interferes w/ purinemetab, cell prolif’n
  47. 47. 42-10Fludarabine Pentostatin
  48. 48.  Substances of microbial origin that preventmammalian cell division Anthracyclines◦ Doxorubicin Intercalates in DNA Inhibits repl’n via action at topoisomerase II Topoisomerase II catalyzes nick in DNA strands Intercalated strand/topoisomerase complex stabilized permanently cleaved helix
  49. 49. ◦ Epirubicin, mitozantrone structurally related◦ SE’s: cardiotoxicity (due to free radical prod’n), bonemarrow suppressionhttp://www.farmakoterapi.uio.no/cytostatika/images/16_1_t.gifMitozantronehttp://www.geocities.com/lubolahchev/Mitoxa4.gif
  50. 50. ◦ Dactinomycin Intercalates in DNA minor groove between adjacent GC pairs Interferes w/ RNA polymerase movement  decr’d transcr’n Also may work through topoisomerase II◦ Bleomycin Glycopeptide Chelates Fe, which interacts w/ O2  Gen’n superoxide and/or hydroxyl radicals Radicals degrade DNA  fragmentation, release of free bases Most effective in G2, also active against cells in G0 Little myelosuppression BUT pulmonary fibrosis
  51. 51. DactinomycinBleomycin
  52. 52.  Work at mitosis Effect tubulin, therefore microtubule activity◦  Prevention spindle form’n OR◦ Stabilize (“freeze”) polymerized microtubules  Arrest of mitosis Other effects due to tubulin defects◦ Phagocytosis/chemotaxis◦ Axonal transport in neurons
  53. 53. http://biotech.icmb.utexas.edu/botany/gifs/vdes.gifVinca Alkaloids
  54. 54. http://biotech.icmb.utexas.edu/botany/gifs/tax.gifTaxanes: Paclitaxel, Docetaxelhttp://home.caregroup.org/clinical/altmed/interactions/Images/Drugs/docetaxe.gif
  55. 55.  Etoposide, teniposide◦ From mandrake root◦ Inhibit mitoch function, nucleoside transport,topoisomerase II Campothecins: irinotecan, topotecan◦ Irinotecan requires hydrolysis  active form◦ Bind, inhibit topoisomerase II◦ Repair is difficult
  56. 56. http://www.chemheritage.org/EducationalServices/pharm/chemo/readings/ages/ages04.gifIronotecanhttp://www.cancerquest.org/images/topotecan.gifTopotecanhttp://www.axxora.com/files/formula/lkt-i6933.gif
  57. 57.  Tumors der’d from tissues responding tohormones may be hormone-dependent◦ Growth inhib’d by hormone antagonists OR otherhormones w/ opposing actions OR inhibitors of relevanthormone Glucocorticoids◦ Inhibitory on lymphocyte prolif’n◦ Used against leukemias, lymphomas
  58. 58.  Estrogens◦ Block androgen effects (ex: fosfestrol)◦ Used to recruit cells in G0  G1, so better targets forcytotoxic drugs Progestogens (ex: megestrol,medroxyprogesterone)◦ Used in endometrial, renal tumors GnRH analogs (ex: goserelin)◦ Inhibit gonadotropin release  decr’d circulatingestrogens
  59. 59.  Hormone antagonists◦ Tamoxifen impt in breast cancer treatment Competes w/ endogenous estrogens for receptor Inhibits transcr’n estrogen-responsive genes◦ Flutamide, cyproterone impt in prostate tumors Androgen antagonists◦ Trilostane, aminoglutethimide inhibit sex hormonesynth at adrenal gland◦ Formestane inhibits aromatase at adrenal gland
  60. 60. http://www.wellesley.edu/Chemistry/chem227/nucleicfunction/cancer/tamoxifen.gifhttp://www.neurosci.pharm.utoledo.edu/MBC3320/images/Flutamide.gifFormestanehttp://www.axxora.com/files/formula/LKT-F5769.gifTrilostanehttp://img.alibaba.com/photo/50310947/Trilostane.jpg
  61. 61. Rang 50.1Antitumor Agents Working through Cell Signalling
  62. 62.  EGFR present on many solid tumors Tyr-kinase type receptors Ligand binding  kinase cascade transcription factor synth◦  incr’d cell prolif’n◦  metastasis◦  decr’d apoptosis Cells expressing EGFR resistant tocytotoxins; poor clinical outcome predicted
  63. 63.  Cetuximab◦ Monoclonal Ab directed against EGFR Erbitux – Famous anti-EGFR AbDrugs Targeting Growth Factor Receptors
  64. 64.  Trastuzumab◦ “Humanized” mousemonoclonal Ab◦ Binds HER2 Membr prot structurallysimilar to EGFR Has integral tyr kinase activity Impt in breast cancer cells◦ May also induce p21 andp27 Cell cycle inhibitorshttp://www.gene.com/gene/products/information/oncology/herceptin/images/moa.jpg
  65. 65.  Imatinib (Gleevec, Glivec)◦ Small inhibitor of kinases◦ Inhibits PDGF activity via its tyr kinase receptor◦ Inhibits Bcr/Abl kinase Cytoplasmic kinase impt in signal transduction Unique to chronic myeloid leukemia◦ Also used against non-small cell lung cancer Gefitinib◦ Similar to Imatinib
  66. 66. http://www.chemistrydaily.com/chemistry/upload/thumb/9/9a/200px-Imatinib_mesylate.pnghttp://dric.sookmyung.ac.kr/NEWS/jul01/gleevecmech.jpgImatinibGefitinib
  67. 67. http://www.wwu.edu/depts/healthyliving/PE511info/cancer/My%20Cancer%20Webs/Symptoms%20and%20Therapy_files/image001.jpg

×